Pharmacokinetic and pharmacodynamic evaluation of ramelteon: an insomnia therapy

Bibliography

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th edition. American Psychiatric Association Publishing, Washington, DC; 2013. Available from: http://psychiatryonline.org/ [Accessed March 2015]
   Google Scholar
• American Academy of Sleep Medicine. International classification of sleep disorders, 3rd edition. American Academy of Sleep Medicine publishing; Darien, IL: 2014
   Google Scholar
• Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3(5 Suppl):S7–10
   PubMed Web of Science ®Google Scholar
• Dopp J, Philips B. Sleep disorders. In: DiPiro J, Talbert R, Yee G, et al. editors. Pharmacotherapy: a pathophysiologic approach. 8th edition. McGraw-Hill; New York: 2011. p. 621–3
   Google Scholar
• Leger D, Poursain B, Neubauer D, Uchiyama M. An international survey of sleeping problems in the general population. Curr Med Res Opin 2008;24:307–17
   PubMed Web of Science ®Google Scholar
• Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep 2007;30:213–18
   PubMed Web of Science ®Google Scholar
• Roth T. Comorbid insomnia: current directions and future challenges. Am J Manag Care 2009;15(Suppl):S6–13
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97–111
   PubMed Web of Science ®Google Scholar
• Hirshkowitz M, Seplowitz-Hafkin RG, Sharafkhaneh A. Sleep disorders. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan & Sadock’s comprehensive textbook of psychiatry. 9th edition. Lippincott Williams & Wilkins; Philadelphia (PA): 2009. p. 2150–77
   Google Scholar
• Gershell L. Insomnia market. Nat Rev Drug Discov 2006;5:15–16
   PubMed Web of Science ®Google Scholar
• Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487–504
   PubMed Web of Science ®Google Scholar
• Huedo-Medina TB, Kirsch I, Middlemass J, et al. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012;345:e8343
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225–33
   PubMed Web of Science ®Google Scholar
• FDA Lunesta prescribing information. Available from: http://www.lunesta.com/PostedApprovedLabelingText.pdf [Last accessed 30 January 2015]
   Google Scholar
• FDA Ambien CR medication guide. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/ucm085908.pdf [Last accessed 30 January 2015]
   Google Scholar
• Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005;66:469–76
   PubMed Web of Science ®Google Scholar
• Weber J, Siddiqui MA, Wagstaff AJ, McCormack PL. Low-dose doxepin: in the treatment of insomnia. CNS Drugs 2010;24:713–20
   PubMed Web of Science ®Google Scholar
• Yeung W, Chung K, Yung K, Ng TH. Doxepin for insomnia: A systematic review of randomized placebo-controlled trials. Sleep Med Rev 2015;19C:75–83
   Google Scholar
• Szabadi E. Selective targets for arousal-modifying drugs: implications for the treatment of sleep disorders. Drug Discov Today 2014;19:701–8
   PubMed Web of Science ®Google Scholar
• Mistlberger RE. Circadian regulation of sleep in mammals: role of the suprachiasmatic nucleus. Brain Res Rev 2005;49:429–54
   PubMed Web of Science ®Google Scholar
• Deurveilher S, Semba K. Indirect projections from the suprachiasmatic nucleus to major arousal-promoting cell groups in rat: implications for the circadian control of behavioural state. Neuroscience 2005;130:165–83
   PubMed Web of Science ®Google Scholar
• Benarroch EE. Suprachiasmatic nucleus and melatonin: reciprocal interactions and clinical correlations. Neurology 2008;71:594–8
   PubMed Web of Science ®Google Scholar
• Cajochen C, Kräuchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 2003;15:432–7
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Delagrange P, Krause DN, et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010;62:343–80
   PubMed Web of Science ®Google Scholar
• Nosjean O, Ferro M, Coge F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000;275:31311–17
   PubMed Web of Science ®Google Scholar
• Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther 2011;17:733–41
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Mulchahey JJ, Scharf MB, et al. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005;66:384–90
   PubMed Web of Science ®Google Scholar
• Neurim Pharmaceutical: information product. Available from: http://www.neurim.com/products/piromelatine/ [Last accessed 30 January 2015]
   Google Scholar
• Zlotos R, Jockers R, Cecon E, et al. MT1 and MT2 melatonin receptors: ligands, oligomers and therapeutic potential. J Med Chem 2014;57:3161–85
   PubMed Web of Science ®Google Scholar
• Uchikawa O, Fukatsu K, Tokunoh R, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem 2002;45:4222–39
   PubMed Web of Science ®Google Scholar
• Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48:301–10
   PubMed Web of Science ®Google Scholar
• Hibberd M, Stevenson SJ. A Phase-I Open-Label Study of the Absorption, Metabolism, and Excretion of (14C)-Ramelteon (TAK-375) Following a Single Oral Dose in Healthy Male Subjects [abstract]. Sleep 2003;26(Suppl):A54
   Google Scholar
• Rozerem® Prescribing Information. Available from: http://general.takedapharm.com/content/file.aspx?applicationcode=2bcc07ca-d9c0-4704-9a28-963127115641&filetypecode=rozerempi&cacheRandomizer=4c69544c-4253-45df-934a-49a085b2d5df [Last accessed 30 January 2015]
   Google Scholar
• Amakye DD, Hibberd M, Stevenson SJ. A Phase I Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ramelteon (TAK-375) in Healthy Male Subjects [abstract]. Sleep 2003;26(Suppl):A54
   Google Scholar
• Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006;46:140–8
   PubMed Web of Science ®Google Scholar
• Cinical trial NCT00914862. Pharmacokinetic and safety of ramelteon between adolescents with insomnia and healthy adults. Available from: clinicaltrials.gov [Last accessed 30 January 2015]
   Google Scholar
• Waldhauser F, Waldhauser M, Lieberman HR, et al. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984;39:307–13
   PubMed Web of Science ®Google Scholar
• Nishiyama K, Nishikawa H, Kato K, et al. Pharmacological characterization of M-II, the major human metabolite of ramelteon. Pharmacology 2014;93:197–201
   PubMed Web of Science ®Google Scholar
• Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos 2010;38:1381–91
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 2007;47:485–96
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Nishikawa H, Doken Y, et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004;27:1319–25
   PubMed Web of Science ®Google Scholar
• Daley JT, Turner RS, Freeman A, et al. Prolonged assessment of sleep and daytime sleepiness in unrestrained Macaca mulatta. Sleep 2006;29:221–31
   PubMed Web of Science ®Google Scholar
• Yukuhiro N, Kimura H, Nishikawa H, et al. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res 2004;1027:59–66
   PubMed Web of Science ®Google Scholar
• Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005;28:303–7
   PubMed Web of Science ®Google Scholar
• Zammit G, Schwartz H, Roth T, et al. Phase III study of ramelteon in a first-night-effect model of transient insomnia. Sleep Med 2005;6:S50–1
   Google Scholar
• McElroy SL, Winstanley EL, Martens B, et al. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol 2011;26:48–53
   PubMed Web of Science ®Google Scholar
• Clinical trial NCT00325728. A double-blind, randomized, placebo-controlled study of the efficacy, safety and tolerability of 8 week treatment of rozerem 8 mg (QHS) in sleep disturbed, mild to moderately severe alzheimer’s disease subjects. Available from: clinicaltrials.gov [Last accessed 30 January 2015]
   Google Scholar
• Gooneratne NS, Gehrman P, Gurubhagavatula I, et al. Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study. J Clin Sleep Med 2010;6:572–80
   PubMed Web of Science ®Google Scholar
• Clinical trial NCT01207050. Pilot study: the effect of rozerem on sleep disturbance after traumatic brain injury. Available from: clinicaltrials.gov [Last accessed 30 January 2015]
   Google Scholar
• Zeitzer JM, Ku B, Ota D, Kiratli BJ. Randomized controlled trial of pharmacological replacement of melatonin for sleep disruption in individuals with tetraplegia. J Spinal Cord Med 2014;37:46–53
   PubMed Web of Science ®Google Scholar
• Clinical trial NCT00337272. Phase IV: treatment of chronic insomnia in patients with breast cancer following completion of chemotherapy. Available from: clinicaltrials.gov [Last accessed 30 January 2015]
   Google Scholar
• Dobkin RD, Menza M, Bienfait KL, et al. Ramelteon for the treatment of insomnia in menopausal women. Menopause Int 2009;15:13–18
   PubMedGoogle Scholar
• Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17–24
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Spence DW, Verster JC, et al. Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis 2011;3:51–65
   PubMedGoogle Scholar
• Mets MA, van Deventer KR, Olivier B, Verster JC. Critical appraisal of ramelteon in the treatment of insomnia. Nat Sci Sleep 2010;2:257–66
   PubMedGoogle Scholar
• Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495–504
   PubMed Web of Science ®Google Scholar
• Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005–14
   PubMed Web of Science ®Google Scholar
• Wang-Weigand S, McCue M, Ogrinc F, Mini L. Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. Curr Med Res Opin 2009;25:1209–13
   PubMed Web of Science ®Google Scholar
• Mayer G, Wang-Weigand S, Roth-Schechter B, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009;32:351–60
   PubMed Web of Science ®Google Scholar
• Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007;5:177–84
   PubMedGoogle Scholar
• Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med 2014;15:385–92
   PubMed Web of Science ®Google Scholar
• Liu J, Wang LN. Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. Int J Clin Pract 2012;66:867–73
   PubMed Web of Science ®Google Scholar
• Kohsaka M, Kanemura T, Taniguchi M, et al. Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia. Expert Rev Neurother 2011;11:1389–97
   PubMed Web of Science ®Google Scholar
• Uchiyama M, Hamamura M, Kuwano T, et al. Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med 2011;12:119–26
   PubMed Web of Science ®Google Scholar
• Uchiyama M, Hamamura M, Kuwano T, et al. Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia. Sleep Med 2011;12:127–33
   PubMed Web of Science ®Google Scholar
• Uchimura N, Ogawa A, Hamamura M, et al. Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study. Expert Rev Neurother 2011;11:215–24
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005;66(Suppl 9):31–41
   PubMed Web of Science ®Google Scholar
• Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006;63:1149–57
   PubMed Web of Science ®Google Scholar
• Miyamoto M. Pharmacology of ramelteon, a selective mt1/mt2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther 2009;15:32–51
   PubMed Web of Science ®Google Scholar
• Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry 2009;70:467–76
   PubMed Web of Science ®Google Scholar
• Todd CM, Forrester MB. Ramelteon ingestions reported to Texas poison centers, 2005-2009. J Emerg Med 2012;43:e189–93
   PubMedGoogle Scholar
• Zammit G, Wang-Weigand S, Rosenthal M, Peng X. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med 2009;5:34–40
   PubMed Web of Science ®Google Scholar
• Mets MA, de Vries JM, de Senerpont Domis LM, et al. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 2011;34:1327–34
   PubMed Web of Science ®Google Scholar
• Richardson G, Wang-Weigand S. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol 2009;24:103–11
   PubMed Web of Science ®Google Scholar
• Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath 2007;11:159–64
   PubMed Web of Science ®Google Scholar
• Kryger M, Wang-Weigand S, Zhang J, Roth T. Effect of ramelteon, a selective MT(1)/MT(2)-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep Breath 2008;12:243–50
   PubMed Web of Science ®Google Scholar
• Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath 2009;13:79–84
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals America, Inc. Rozerem™ (ramelteon) tablets: prescribing information. Available from: http://www.rozeremhcp.com/ Last accessed 30 January 2015]
   Google Scholar
• Fourman LT, Robert Meyer B. Autoimmune hepatitis in association with ramelteon. J Clin Gastroenterol 2013;47:651–4
   PubMed Web of Science ®Google Scholar
• Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clin Pract 2007;61:835–45
   PubMed Web of Science ®Google Scholar
• Withdrawal assessment report for ramelteon. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500064663.pdf [Last accessed 30 January 2015]
   Google Scholar
• Takeda news (October – December 2011). Available from: www.takeda.com/news/2011/20111007_3902.html [Last accessed 30 January 2015]
   Google Scholar
• Gross PK, Nourse R, Wasser TE. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med 2009;5:28–33
   PubMed Web of Science ®Google Scholar
• Shimizu N, Sugimoto K, Nozawa M, et al. Efficacy of ramelteon in patients with insomnia and nocturia. LUTS 2013;5:69–74
   Web of Science ®Google Scholar
• Howland RH. Delirium and its prevention with melatonergic drugs. J Psychosoc Nurs Ment Health Serv 2014;52:13–16
   Web of Science ®Google Scholar
• Norris ER, Karen B, Correll JR, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord 2013;144:141–7
   PubMed Web of Science ®Google Scholar
• Yanagihara M, Nakamura M, Usui A, et al. The melatonin receptor agonist is effective for free-running type circadian rhythm sleep disorder: case report on two sighted patients. Tohoku J Exp Med 2014;234:123–8
   PubMed Web of Science ®Google Scholar
• Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7(4):312–18
   PubMed Web of Science ®Google Scholar
• Wang-Weigand S, Watissée M, Roth T. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia. Sleep Med 2011;12:920–3
   PubMed Web of Science ®Google Scholar